Combination therapy with apilimod and glutamatergic agents
Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.
1. A method for treating a neurological disease or disorder in a subject in need thereof, the method comprising administering to the subject a PIKfyve inhibitor and a glutamatergic agent.
2. The method of claim 1 , wherein the PIKfyve inhibitor is apilimod or a pharmaceutically acceptable salt thereof.
3. The method of claim 2 , wherein the apilimod is apilimod dimesylate.
4. The method of claim 1 , wherein the glutamatergic agent is selected from a glutamate transporter modulating agent and a glutamate receptor antagonist.
5. The method of claim 4 , wherein the glutamate transporter modulating agent is an excitatory amino acid reuptake inhibitor.
6. The method of claim 4 , wherein the glutamate receptor antagonist is an N-methyl-D-aspartate (NMDA) receptor antagonist.
7. The method of claim 4 , wherein the glutamate receptor antagonist is selected from AP5 (R-2-amino-5-phosphonopentanoate), AP7 (2-amino-7-phosphonoheptanoic acid), CNQX (6-cyano-7-nitroquinoxaline-2,3-dione), CPPene (3-[(R)-2-carboxypiperazin-4-yl]-prop-2-enyl-1-phosphonic acid), NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione), and selfotel (CGS-19755).
8. The method of claim 4 , wherein the glutamate receptor antagonist is selected from amantadine, atomoxetine, AZD6765, agmatine, gacyclidine, ketamine, memantine, eliprodil, and delucemin.
9. The method of claim 1 , wherein the glutamatergic agent is selected from BHV-5000, lamotrigine, lanicemine, riluzole, trigriluzole, and topiramate.
10. The method of claim 1 , wherein the PIKfyve inhibitor is in a composition in an oral dosage form or a sublingual dosage form.
11. The method of claim 1 , wherein the glutamatergic agent and the PIKfyve inhibitor are administered in the same composition.
12. The method of claim 1 , wherein the glutamatergic agent and the PIKfyve inhibitor are administered in separate compositions.
13. The method of claim 1 , wherein the neurological disease or disorder is selected from Alzheimer's disease, amyotrophic lateral sclerosis (ALS), attention deficit hyperactivity disorder, autism, cerebellar ataxia, Charcot-Marie-Tooth disease, Creutzfeldt-Jakob disease, dementia, epilepsy, Friedreich's ataxia, Huntington's disease, multiple sclerosis, obsessive compulsive disorder (OCD), Parkinson's disease, Rett syndrome, senile chorea, spinal ataxia, spinal cord injury, supranuclear palsy, and traumatic brain injury.
14. The method of claim 1 , wherein the neurological disease or disorder is dementia.
15. The method of claim 14 , wherein the dementia is selected from AIDS dementia complex (ADC), dementia associated with Alzheimer's disease (AD), dementia pugilistica, diffuse Lewy body disease, frontotemporal dementia, mixed dementia, senile dementia of Lewy body type, and vascular dementia.
16. The method of claim 1 , wherein the neurological disease or disorder is amyotrophic lateral sclerosis (ALS).
17. The method of claim 1 , wherein the neurological disease or disorder is frontotemporal dementia.
18. The method of claim 1 , wherein the subject is human.
19. The method of claim 1 , wherein the subject is further administered an antioxidant.
20. The method of claim 19 , wherein the antioxidant is edaravone.
21. A method for treating a neurological disease or disorder in a subject in need thereof, the method comprising administering to the subject a PIKfyve inhibitor and an antioxidant.